In vivo, an excellent pharmacokinetic profile allowed APG-115 to effectively activate wild-type p53 in an osteosarcoma xenograft mouse model following a single oral dose, where it afforded complete tumor remission when administered at 100 mg/kg daily for 14 days. The gene discussed is TP53; the disease is neoplasm.